Pharmacogenomic Study to Predict Neurotoxicity of Oxaliplatin

Pharmacogenomic Study to Predict Toxicity and Response in Colorectal Cancer Patients Treated With Oxaliplatin-based Chemotherapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00977717

Enrollment

100

Registered

2009-09-16

Start date

2008-09-30

Completion date

2010-04-30

Last updated

2010-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Curatively Resected Stage III Colon Cancer

Keywords

oxaliplatin, neuropathy, SNPs

Brief summary

In order to explore genetic factors that may determine the neurotoxicity of oxaliplatin-based chemotherapy, germinal gene polymorphisms will be analyzed.

Detailed description

To investigate the impact of single nucleotide (SNP) polymorphism on the toxicity profile in colorectal cancer patients treated with FOLFOX chemotherapy, 10 cc of blood will be drawn in EDTA tube for extraction. DNA will be extracted from peripheral blood samples using DNA isolation kit, and SNP polymorphisms will be evaluated.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* aged 18 or older * curatively resected colon adenocarcinoma * pathologically staged III * adequate performance status * adequate major organ functions * to be treated with adjuvant FOLFOX chemotherapy * written informed consent

Exclusion criteria

* those who disagree the study

Design outcomes

Primary

Measure	Time frame
neuropathy	six months

Countries

South Korea

Outcome results